Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

18.95
1,240,915

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Surprise Coming for Clovis Oncology (CLVS) This Earnings Season?

by Zacks Equity Research

Clovis Oncology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

    AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan

    by Zacks Equity Research

    AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.

      AstraZeneca's Lynparza Label Now Includes Breast Cancer

      by Zacks Equity Research

      AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

        Clovis Up More Than 50% in 2017: What's Driving the Stock?

        by Zacks Equity Research

        Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

          Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

          by Zacks Equity Research

          Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

            Clovis' sNDA for Rubraca Gets Priority Review in the U.S.

            by Zacks Equity Research

            The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.

              TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU

              by Zacks Equity Research

              TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.

                Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

                by Zacks Equity Research

                Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

                  Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

                  by Zacks Equity Research

                  With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                    What to Expect from Keryx (KERX) This Earnings Season?

                    by Zacks Equity Research

                    Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.

                      What's in Store for Intrexon (XON) This Earnings Season?

                      by Zacks Equity Research

                      Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.

                        Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

                        by Zacks Equity Research

                        Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.

                          Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?

                          by Zacks Equity Research

                          AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.

                            Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?

                            by Zacks Equity Research

                            ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.

                              Will Endocyte (ECYT) Disappoint This Earnings Season?

                              by Zacks Equity Research

                              Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.

                                Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?

                                by Zacks Equity Research

                                Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.

                                  Is Aerie (AERI) Poised for a Beat This Earnings Season?

                                  by Zacks Equity Research

                                  Aerie Pharmaceuticals (AERI) is looking solid on strong prospects of its lead candidate, Rhopressa. We expect investors to focus on further pipeline updates on the third-quarter call.

                                    What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?

                                    by Zacks Equity Research

                                    Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.

                                      What's in the Cards for Arena (ARNA) This Earnings Season?

                                      by Zacks Equity Research

                                      Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.

                                        Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?

                                        by Zacks Equity Research

                                        ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.

                                          Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

                                          by Zacks Equity Research

                                          Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.

                                            Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?

                                            by Zacks Equity Research

                                            Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.

                                              What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?

                                              by Zacks Equity Research

                                              Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.

                                                What's in the Offing for Intercept (ICPT) in Q3 Earnings?

                                                by Zacks Equity Research

                                                Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.

                                                  What's in the Cards for Geron (GERN) this Earnings Season?

                                                  by Zacks Equity Research

                                                  With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.